9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. 9 Meters Biopharma, Inc. has a collaboration with the Duke Clinical Research Institute to support the clinical development of NM-002. The company is headquartered in Raleigh, North Carolina.
IPO Year: 2018
Exchange: NASDAQ
Website: 9meters.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2021 | $5.00 | Outperform | BMO Capital Markets |
BMO Capital Markets initiated coverage of 9 Meters Biopharma with a rating of Outperform and set a new price target of $5.00
Citigroup initiated coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $3.00
Brookline Capital resumed coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $6.00
Oppenheimer initiated coverage of 9 Meters Biopharma with a rating of Outperform and set a new price target of $6.00
25-NSE - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
144 - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)
8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)
8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)
8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)
PRE 14A - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)
8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)
10-Q - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)
8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)
SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SC 13G - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SC 13D/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SC 13G - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SC 13D/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SC 13D/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SC 13D/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,
Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer."We're very pleased to have Ms. Sensenig join the 9 Meters team as Chief Financial Officer with over twenty years of business and strategic financial leadership experience at both early-stage and large biotechnology companies," said John Temperato, President & Chief
RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications."We are very excited to have such talented individuals, each with lengthy and accomplished pharmaceutical and biotech backgrounds, join the 9 Meters team during this critical time of growth for our company," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma. "Ms. Liu's
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Samantha Ventimiglia to its Board of Directors.Ms. Ventimiglia currently serves as Senior Vice President, U.S. Public Affairs at Vertex Pharmaceuticals, Inc., where she is responsible for developing and overseeing the company's policy, government affairs and patient advocacy strategy, including building relationships with state and federal government officials, industry organizations, patient groups and other stakeholders. Previo
RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors. Mr. Rice is the president and co-founder of LifeSci Advisors, a life sciences investor relations consultancy, and the co-founder of LifeSci Capital, a research-driven investment bank. Previously, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also a Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which inc
Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimenClinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarterRALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended Septembe
Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announcedVurolenatide End-of-Phase 2 meeting with FDA on track for 3QCash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt financing extends cash runway into 4Q 2023RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.John Temperato, President & Chief Exe
On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in JuneCash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is
RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2021.John Temperato, President & CEO of 9 Meters Biopharma, commented: "2021 was an exceptionally productive year for 9 Meters as we significantly advanced our pipeline, particularly our lead assets vurolenatide for short bowel syndrome (SBS) and larazotide for celiac disease. We look forward to meaningful data readouts in the second quarte
- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 -- Larazotide Phase 3 for celiac disease interim analysis expected in Q2 2022 -- Appointed Samantha Ventimiglia of Vertex to the Board of Directors -- Quarter ending cash of $53.6 million is expected to fund operations into 2023 -RALEIGH, NC / ACCESSWIRE / November 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today provided a business update and reported financial results for the t
Conference Call Scheduled for August 12, 2021 RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in the Biopharma Spotlight Series: Innovation in GI Conference Call hosted by Gary Nachman and BMO Capital Markets. Please see additional details below:Biopharma Spotlight Series: Innovation in GI Conference Call Date: Thursday, August 12th, 2021Time: 11:35 am Eastern TimeTitle: DEEP DIVE ON SHORT BOWEL SYNDROME Webcast link: https://bmo.qumucloud.com/view/2021-biopharma-9metersManagement: John Temperato, President & CEO Patrick Griffin , Chief Medical Officer* a replay will be available following
- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) -- First planned indication is Prader-Willi Syndrome-- IND-enabling studies ongoing with first-in-human studies anticipated in 2023 -- Transaction does not impact corporate guidance and company remains fully financed into 2023 with co-lead programs' in short bowel syndrome (Phase 2) and in celiac disease (Phase 3) -RALEIGH, NC / ACCESSWIRE / July 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company has acquired global development rights to a proprietary an
FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure Announced positive topline data in December for NM-002, a proprietary long-acting GLP-1, in a Phase 1b/2a trial for SBS Company's R&D day on March 23rd to include additional Phase 1b/2a study data on parenteral support, pharmacokinetics and quality of life Phase 3 interim analysis and topline data for larazotide in celiac disease now anticipated in 2022 due to COVID-19 impact on patient enrollment Raised over $58 million from prominent institutional healthcare investors in 2020 Research & Develop
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
4/A - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.Mark Sirgo, Chairman of the Board of 9 Meters, stated, "On behalf of the Board of Directors, I want to thank John for his service and dedication to the Company." The Board of Directors has appointed Bethany Sensenig, Chief Financial Officer of 9 Meters, to serve as interim Chief Executive Officer in addition to her current responsibiliti
RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "We are enthusiastic about the potential of vurolenatide and NM-136 to deliver value to patients. We are exploring options to fund further advancement of these assets, including financing and other strategic alternatives."Clinical Development and Business HighlightsPresentations on vurolenatide and SBS at ASPEN 2
RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136
RALEIGH, NC / ACCESSWIRE / March 28, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2022."Our priority for 2023 remains to progress our Phase 3 vurolenatide program for short bowel syndrome including securing a clinical development and commercialization partner," commented John Temperato, President and Chief Executive Officer of 9 Meters Biopharma. "We firmly believe vurolenatide can establish a new standard of care in the treatment
RALEIGH, NC / ACCESSWIRE / March 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today the closing of its previously announced registered direct offering of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock equivalent) and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.35 per share, are immediately exercisable, and expire three and one-half years follo
RALEIGH, NC / ACCESSWIRE / March 14, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock equivalent) and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $1.35 per share, will b
RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference.Oppenheimer 33rd Annual Healthcare ConferenceDate: Monday, March 13, 2023Time: 3:20 PM ETWebcast linkThe presentation will highlight the Company's pipeline, with a focus on vurolenatide, its long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome, as well as upcoming milestones.The presentation will also be available in th
RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters is scheduled to present on Monday, February 6, 2023, at 10:00 AM ET as part of the BIO CEO & Investor Conference being held in New York City.The presentation, which is accessible to registered conference attendees, will highlight the Company's pipeline, with a focus on vurolenatide, its long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome, as well as upcoming milestones.About 9 Meters Biopharm
Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,
Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependenceStudy design allows for the assessment of the entirety of the short bowel syndrome patient populationUS IRB approval secured; study to include up to 50 sites in North America and Europe and remains on track with study initiation as early as end-of-yearRALEIGH, NC / ACCESSWIRE / November 29, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced the design of its Phase 3 clinical trial of vurolenatide for adults with shor
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock rose 36.8% to $0.1 during Tuesday's after-market session. At the close, 9 Meters Biopharma's trading volume reached 4.7 million shares. This is 1095.7% of its average volume over the last 100 days. The company's market cap stands at $1.4 million. ViewRay (NASDAQ:VRAY) stock moved upwards by 11.99% to $0.03. Trading volume for this security closed at 19.2 million, accounting for 150.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.1 million. Plus Therapeutics (NASDAQ:PSTV) stock increased by 10.36% to $2.45. The company's market cap stands at $6.1 million. PAVmed (NASDAQ:PAVM) sha
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 33.8% to $4.63 during Tuesday's regular session. Trading volume for Bullfrog AI Hldgs's stock is 42.6 million as of 13:30 EST. This is 8458.3% of its average full-day volume over the last 100 days. The company's market cap stands at $28.2 million. Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock rose 32.66% to $19.82. Trading volume for Kiniksa Pharmaceuticals's stock is 3.0 million as of 13:30 EST. This is 719.4% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 billion. As per the press release, Q2 earnings came out today. Galecto (NASDAQ:GLTO) shares rose 28.51% to $3.02. As of 13:30
Gainers Aurora Acquisition Corp. (NASDAQ:AURC) shares jumped 192% to $30.54. Inpixon (NASDAQ:INPX) gained 117% to $0.33 after the company agreed to merge with XTI Aircraft Company. Electra Battery Materials Corporation (NASDAQ:ELBM) shares shot up 71.5% to $2.11 after jumping 22% on Monday. Electra Battery Materials said its battery grade cobalt supply agreement with LG Energy Solution has been extended and expanded from terms initially announced in Sept. 2022. Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) shares gained 35.3% to $4.68 after the company announced US patent for novel prodrugs of mebendazole and their use in treating cancer. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) climb
On Tuesday, 56 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS). 9 Meters Biopharma (NASDAQ:NMTR) was the smallest company by market cap to set a new 52-week low. Humanigen (NASDAQ:HGEN)'s stock came under the most pressure, trading down 73.22% to reach a new 52-week low. NeuBase Therapeutics (NASDAQ:NBSE) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. On Tuesday, the following stocks set new 52-week lows: Apellis Pharmaceuticals (NASDAQ:APLS) stock drifted down 2.25% on Tuesday morning to hi
On Monday morning, 70 companies achieved new lows for the year. Interesting Facts About Today's 52-Week Lows: Estee Lauder Cos (NYSE:EL) was the largest firm by market cap to set a new 52-week low. 9 Meters Biopharma (NASDAQ:NMTR) was the smallest firm on a market cap basis to set a new 52-week low. AppHarvest (NASDAQ:APPH) was the biggest loser, trading down 70.3% to reach its 52-week low. SWK Holdings (NASDAQ:SWKH) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low. Over the course of the first half-hour of trading on Monday, the following stocks hit new 52-week lows: Estee Lauder Cos (NYSE:EL) stock broke to
During Thursday's session, 40 stocks hit new 52-week lows. 52-Week Low Highlights: The largest company by market cap to set a new 52-week low was Crown Castle (NYSE:CCI). The smallest company by market cap to set a new 52-week low was Ucommune International (NASDAQ:UK). Vir Biotechnology (NASDAQ:VIR)'s stock fell the most, as it traded down 44.38% to reach a new 52-week low. Yunji (NASDAQ:YJ)'s stock rebounded the most, as it traded up 0.0% after dropping to a new 52-week low. Here are all the stocks that set new 52-week lows on Thursday: Crown Castle (NYSE:CCI) shares set a new 52-week low of $103.22. The stock traded down 5.62%. Kenvue (NYSE:KVUE) stock broke to a new 52-we
Gainers Dynatronics (NASDAQ:DYNT) stock moved upwards by 17.7% to $0.92 during Wednesday's after-market session. The market value of their outstanding shares is at $3.7 million. Novan (NASDAQ:NOVN) shares rose 9.99% to $0.2. Trading volume for this security closed at 4.6 million, accounting for 680.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.6 million. Trinity Biotech (NASDAQ:TRIB) shares moved upwards by 8.79% to $1.11. The company's market cap stands at $42.4 million. 9 Meters Biopharma (NASDAQ:NMTR) shares moved upwards by 8.32% to $0.18. 9 Meters Biopharma's trading volume hit 901.9K shares by close, accounting for 3
Gainers Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) rose 43% to $6.91. SMX (Security Matters) Public Limited Company (NASDAQ:SMX) jumped 39.1% to $0.2031. Security Matters received a notice of allowance for its U.S. patent application 17/285,167 Titled "System And Method For Detection And Identification Of Foreign Elements In A Substance By X-Ray Or Gamma-Ray Detection And Emission." Carvana Co. (NYSE:CVNA) shares jumped 32.3% to $52.67 after the company reported better-than-expected second-quarter sales and guided positive adj. EBITDA for the third quarter. Carvana entered into distribution agreement with Citigroup, Moelis relating to offering of up to $1 billion of class A common stock
Gainers enVVeno Medical (NASDAQ:NVNO) shares moved upwards by 29.4% to $4.71 during Wednesday's regular session. Trading volume for enVVeno Medical's stock is 595.4K as of 13:30 EST. This is 1331.0% of its average full-day volume over the last 100 days. The company's market cap stands at $44.6 million. 60 Degrees (NASDAQ:SXTP) stock moved upwards by 28.92% to $3.12. The current volume of 12.8 million shares is 208.1% of 60 Degrees's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $17.3 million. Harrow Health (NASDAQ:HROW) shares rose 19.64% to $21.86. Trading volume for this security as of 13:30 EST is 2.6 million, which is 50
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 1.09% to 34,961.65 while the NASDAQ rose 0.91% to 14,374.77. The S&P 500, also rose, gaining, 0.77% to 4,557.83. Check This Out: Ethereum Slides But Remains Above $1,900; 1inch Network Becomes Top Loser Leading and Lagging Sectors Energy shares climbed by 1.4% on Tuesday. In trading on Tuesday, real estate shares fell by 1.5%. Top Headline Lockheed Martin Corp (NYSE:LMT) reported better-than-expected second-quarter earnings. Lockheed Martin reported second-quarter FY23 net sales growth of 8.1% year-over-year to $16.69 billion, above the consen